History of Chronic Toxicity and Animal Carcinogenicity Studies for Pharmaceuticals

Veterinary Pathology

Volumn 50, Issue 2, 2013, Pages 324-333

  Jacobs, A C ^a   Hatfield, K P ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

carcinogenicity tests; historical aspects; oral contraceptives; pharmaceutical preparations; policy

Indexed keywords

EID: 84874815112     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1177/0300985812450727     Document Type: Review

References (57)

1. Alden CL,Lynn A,Bourdeau A, et al.A critical review of the effectiveness of rodent pharmaceutical carcinogenesis testing in predicting for human risk.Vet Pathol. 2011;48:772-784.
2. AltTox.org. Toxicity testing overview. http://alttox.org/ttrc/tox-test-overview/. 2009.
3. Bailer AJ,Portier CJ.Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples.Biometrics. 1988;44:417-431.
4. Carcinogenicity Testing: A Report of the Panel on Carcinogenicity of the Cancer Research Commission of the UICC. Berenblum I, ed. Geneva: International Union Against Cancer; 1969:.
5. Berenblum I.Irritation and carcinogenesis.Archive Pathol. 1944;38:233-244.
6. Berenblum I.The mechanism of carcinogenesis: a study of the significance of cocarcinogenic action and related phenomena.Cancer Res. 1941;1:807-814.
7. Berenblum I.The modifying influence of dichloro-ethyl sulphide on the induction of tumours in mice by tar.J Pathol Bacteriol. 1929;32:425-434.
8. Berliner VR. U.S.Food and Drug Administration requirements for toxicity testing of contraceptive products.Acta Endocrinol Suppl (Copenhagen). 1974;185:240-265.
9. Boorman G,Montgomery C,Eustis S, et alHandbook of Carcinogen Testing. Milman HWeisburger E, ed. Park Ridge, NJ: Noyes Publications; 1985:345-357.
10. Brix AE,Hardisty JF,McConnell EECancer Risk Assessment. Hsu C-HStedeford T, ed. Hoboken, NJ: John Wiley & Sons; 2010:699-715.
11. D'Aguanno W.Drug-toxicity evaluation: preclinical aspects. In: FDA introduction to total drug quality.DHEW Publication (FDA). 1973;74-3006:35-40.
12. Finkel MJ,Berliner VR.The extrapolation of experimental findings (animal to man): the dilemma of the systemically administered contraceptives.Bull Soc Pharmacol Environ Pathol. 1973;4:13-18.
13. Geil RG,Lamar JK.FDA studies of estrogen, progestogens, and estrogen/progestogen combinations in the dog and monkey.J Toxicol Environ Health. 1977;3:179-193.
14. Goldenthal E.Contraceptives, estrogens, and progestogens: a new FDA policy on animal studies.FDA Papers. 1969;3:15.
15. Goldenthal E.Current views on safety evaluation of drugs.FDA Papers. 1968;2:13-18.
16. International Conference on Harmonization ICH M3(R2) Guideline. Nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. 2010.
17. International Conference on Harmonization ICH S1A Guideline. The need for carcinogenicity studies of pharmaceuticals. 1996.
18. International Conference on Harmonization ICH S1B. Testing for carcinogenicity of pharmaceuticals. 1998.
19. International Conference on Harmonization ICH S1C(R2) Guideline. Dose selection for carcinogenicity studies of pharmaceuticals. 2008.
20. International Conference on Harmonization ICH S6(R1) Guideline. Addendum to ICH S6: preclinical safety evaluation of biotechnology-derived pharmaceuticals. 2011.
21. International Conference on Harmonization ICH S9 Guideline. Nonclinical evaluation for anticancer pharmaceuticals. 2010.
22. International Harmonization of Nomenclature and Diagnostic Criteria for Lesions in Rats and Mice Program (INHAND). http://www.toxpath.org/inhand.asp. 2012.
23. Jacobs A.Prediction of 2-year carcinogenicity study results for pharmaceutical products: how are we doing?.Toxicol Sci. 2005;88:18-23.
24. Jordan A.FDA requirements for nonclinical testing of contraceptive steroids.Contraception. 1992;46:499-509.
25. Larsson KS,Machin DSafety Requirements for Contraceptive Steroids. Michal F, ed. Cambridge, UK: Cambridge University Press; 1989:230-269.
26. Lehman AJ,Laug EP,Woodward G, et al.Procedures for the appraisal of the toxicity of chemicals in food.Food Drug Cosmet Law Q. 1949;4:412-434.
27. Lehman AJ,Patterson WI,Davidow B, et al.Procedures for the appraisal of the toxicity of chemicals in foods, drugs and cosmetics.Food Drug Cosmet Law J. 1955;10:679-748.
28. Lin KK.CDER/FDA formats for submission of animal carcinogenicity study data.Drug Information J. 1998;32:43-52.
29. Lin KK,Rahman MA.Overall false positive rates in tests for linear trend in tumor incidence in animal carcinogenicity studies of new drugs.J Biopharm Stat. 1998;8:1-15.
30. Linhart MS,Cooper J,Martin RL, et al.Carcinogenesis bioassay data system.Comput Biomed Res. 1974;7:230-248.
31. McConnell EE,Solleveld HA,Swenberg JA, et al.Guidelines for combining neoplasms for evaluation of rodent carcinogenesis studies.J Natl Cancer Inst. 1986;76:283-289.
32. McKenzie BE.Guidelines and requirements for the evaluation of contraceptive steroids.Toxicol Pathol. 1989;17:377-384.
33. DHEW Publ. (NIH) 76-801. Bethesda, MD: National Cancer Institute; 1976:1-65.
34. Portier CJ,Bailer AJ.Testing for increased carcinogenicity using a survival-adjusted quantal response test.Fundam Appl Toxicol. 1989;12:731-737.
35. FDA confirms new requirements for steroid testing.Outlook. 1988;6:10.
36. FDA may follow WHO guidelines for contraceptive steroid testing.Outlook. 1987;5:9-10.
37. Rahman MA,Lin KK.A comparison of false positive rates of peto and poly-3 methods for long-term carcinogenicity data analysis using multiple comparison adjustment method suggested by Lin and Rahman.J Biopharm Stat. 2008;18:949-958.
38. Sistare FD,Jacobs ACAlternative Toxicological Methods. Katz SASalem H, ed. Boca Raton, FL: CRC Press; 2003:391-412.
39. Sistare FD,Morton D,Alden C, et al.An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines.Toxicol Pathol. 2011;39:716-744.
40. Toxicol Pathol. 2001;29 (1 suppl): 1-351.
41. US Food and Drug Administration. Drugs@FDA Database. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. 2012.
42. US Food and Drug Administration. FDA history: part I. http://www.fda.gov/AboutFDA/WhatWeDo/History/Origin/ucm054819.htm. 2009.
43. Rockville, MD: Food and Drug Administration; 1987:.
44. Proceedings of the Obstetrics and Gynecology Advisory Committee: "Current Criteria for Evaluation of Progestational Agents and Oral Contraceptives: Preclinical Investigations." Rockville, MD: Food and Drug Administration; 1965:.
45. Weisburger J,Weisburger E.Tests for animal carcinogens.Methods Cancer Res. 1967;1:307-398.
46. Weisburger JH,Williams GMChemical Carcinogens. 2nd ed. Washington, DC: American Chemical Society; 1984:1323-1373.Searle CE, ed. Washington, DC: American Chemical Society; 1984:1323-1373.
47. Weisburger JH,Williams GM.Carcinogen testing: current problems and new approaches.Science. 1981;214:401-407.
48. Woodard G,Calvery HO.Acute and chronic toxicity.Industrial Med. 1943;12:55-59.
49. Depot-medroxyprogesterone acetate (DMPA) and cancer: memorandum from a WHO meeting.Bull World Health Organ. 1993;71:669-676.
50. World Health Organization. Guidelines for the toxicological and clinical assessment and post-registration surveillance of steroidal contraceptive drugs. WHO Special Programme of Research, Development and Research Training in Human Reproduction, Geneva. 1987. Document number HRP/SP.REP/87.1.
51. Safety requirements for contraceptive steroids.Bull World Health Organ. 1988;66:265-266.
52. Breast cancer and combined oral contraceptives: results from a multinational study.Br J Cancer. 1990;61:110-119.
53. Breast cancer and depot-medroxyprogesterone acetate: a multinational study.Lancet. 1991;338:833-838.
54. Yamagiwa K,Ichikawa K.Experimental study of the pathogenesis of carcinoma.CA Cancer J Clin. 1977;27:174-181.
55. Yamagiwa K,Ichikawa K.Experimental study of the pathogenesis of carcinoma.J Cancer Res. 1918;3:1-29.
56. Zbinden G.Pre-clinical evaluation of contraceptive steroids: regulatory requirements and scientific expectations.Hum Reprod. 1986;1:401-404.
57. Zbinden G.The problem of the toxicologic examination of drugs in animals and their safety in man.Clin Pharmacol Ther. 1964;5:537-545.